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Prevalence rate of laboratory defined aspirin resistance 




Background: Cardiovascular disease (CVD) is the first cause of mortality worldwide, with 
all the healthcare systems facing this very challenging issue. Aspirin continues to be the 
major gold-standard treatment worldwide in the prevention of thrombotic disease in 
patients with CVD, even though not all individuals respond to antiplatelet therapy in a 
similar way, being resistant to aspirin. The aim of this study was to determine the 
prevalence of laboratory defined aspirin resistance in CVD patients worldwide. 
Methods: Relevant articles were identified through searching EMBASE, PubMed/ 
MEDLINE, ISI /Web of Science, Scopus, and the Cochrane Library, from January 2000 to 
February 2018. The methodological quality of the included studies was critically appraised 
using the Newcastle-Ottawa scale. The pooled prevalence of laboratory defined aspirin 
resistance was computed using the Der Simonian-Laird random-effect model. 
Results: We included 65 studies, with a total of 10,729 patients. The overall prevalence of 
laboratory defined aspirin resistance in CVD patients was 24.7% ([95%CI 21.4-28.4]. 
Women were found to be at increased risk of laboratory defined aspirin resistance 
compared to men, with an odds ratio of 1.16 [95%CI 0.87-1.54] 
Conclusion: Doctors and healthcare providers should pay special attention to aspirin 
resistance since lack of awareness could cause problems and increase mortality in these 
patients, if not properly treated with higher aspirin doses. 
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Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the 
healthcare systems facing this very challenging issue. The World Health Organization 
(WHO) estimates that 31% of the world's deaths are due to CVD, with around 17.7 million 
CVD-related deaths that occurred in 2015. Approximately 7.4 million of these deaths were 
due to heart disease and 6.7 million deaths were due to stroke (1). More than three-quarters 
of CVD-related deaths occur in low- and middle-income countries. The most important 
risk factors for heart disease and stroke are unhealthy diet, physical inactivity, tobacco and 
alcohol use, which lead to high blood pressure, sugar, fat, overweight and obesity (2). 
Platelet activation plays an important role in the development of CVD. Antiplatelet therapy 
prevents platelet aggregation and thrombosis, and can be used in primary and secondary 
prevention of CVD (3). Despite the development of next-generation drugs, aspirin 
continues to be the major gold-standard treatment worldwide in the prevention of 
thrombotic disease in patients with CVD (4).  
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From a biochemical standpoint, aspirin inhibits the 
conversion of arachidonic acid to thromboxane A2, the main 
metabolite of prostaglandin synthesis, via cyclooxygenase 
(COX) (5). Even low daily aspirin doses (in the range 75-
150 mg) are able to suppress biosynthesis of thromboxane, 
inhibiting the accumulation of platelets, and reducing the 
risk of CVD (6). However, aspirin does not always prevent 
the formation of thromboxane A2 due to failure to inhibit 
platelet COX (7). As such, all individuals do not respond to 
antiplatelet therapy in a similar way; some people suffer 
from thromboembolic events despite ongoing antiplatelet 
therapy (8, 9). The mechanism of resistance to aspirin is still 
unclear. Different patients may require different doses of 
aspirin to inhibit platelet function (10) and this calls up for a 
personalized treatment. 
Several studies have been conducted to evaluate the rate 
of resistance to aspirin in CVD patients. Therefore, the aim 
of this study was to determine the prevalence of aspirin 
resistance by conducting a systematic review and meta-




The research question of the present work is the 
worldwide prevalence rate of laboratory defined aspirin 
resistance in CVD patients. This is a systematic review and 
meta-analysis that identified aspirin resistance studies with 
an assessment of its adverse effects on cardiovascular 
patients. There are several measurement methods to 
investigate platelet function test, Findings showed that the 
blood test is more sensitive than urine level, therefore, the 
present study mostly used two methods of platelet 
function test and verify now aspirin assay, Some studies also 
used platelet aggregation multiple method (11). Findings of 
this study were reported on the basis of the “Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses”(PRISMA) guidelines (12). We searched different 
scholarly electronic databases, such as EMBASE, 
PUBMED/MEDLINE, ISI/Web of Science, Scopus, and the 
Cochrane Library, from January 2000 to February 2018. To 
find more potentially relevant studies, the reference list of 
the included studies was also hand-searched. After the 
search, all records were entered to the EndNote Reference 
Manager X8. At this point, all duplicate articles were 
deleted. Using the Boolean operators (AND, OR), the search 
strategy was performed as follows: (“platelet resistance” OR 
“drug resistance” OR “acetylsalicylic acid” OR aspirin OR 
“antiplatelet platelets” OR “aspirin resistance”) AND 
(“cardiovascular disease” OR “ischemic heart disease” OR 
“acute coronary syndrome”). A total of 2047 studies were 
reached from databases search, after deletion of the number 
650 duplicates, 987 unrelated studies and 204 articles on the 
base abstract were excluded, 138 studies were included to 
title and abstract screening. In addition, we found 32 studies 
based on other sources. A total of 138 studies full texts were 
resumed and reviewed based on inclusion criteria. Finally, 
65 studies with 10,729 participants were subjected. 
Studies were included if: i) designed as cross-sectional, 
cohort or case-control investigations; ii) studies whose data 
were appropriate for the calculation of the prevalence rate; 
iii) patients with a proper clinically established diagnosis of 
CVD; and iv) peer reviewed studies published in English. 
Studies were excluded if: i) designed as letters to editor, 
editorials, commentaries, case reports or case series and 
reviews; ii) overlapping studies (in case of repeated/ 
duplicate/redundant studies, the most comprehensive ones 
were selected); iii) studies whose data did not allow the 
calculation of the prevalence rate; and iv) studies whose full-
text could not be accessed 
Two of the authors independently selected the studies on 
the basis of these criteria, and in case of disagreement, a 
third person was used as the referee and eventually resolved 
the issue through discussion. 
Data extraction: After selecting the studies, two authors 
independently extracted and collected the data from the 
included studies: namely, the surname of the first author of 
the article, year of publication, country of study, number of 
participants in the study (based on gender, if available),  type 
of laboratory-defined aspirin resistance,  prevalence rate, and 
mean age or age range of participants. Before analysis we 
certified the precision of the data. We revised any unequal 
data and adjusted accordingly. 
Assessment of methodological quality: The 
methodological quality of the included studies was critically 
appraised using the Newcastle-Ottawa (NOS) scale (13). 
Three, two and five stars were assigned to the scale items 
based on the three domains (selection of study participants, 
control of confounders and outcome of interest), 
respectively. Based on the overall score, studies were 
divided into three groups: high (1-4 stars), medium (5-7 
stars) and low (8-10 stars) bias. 
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Statistical analysis: The pooled prevalence of laboratory-
defined aspirin resistance was computed using the Der 
Simonian-Laird random-effect model with its 95% 
confidence interval (CI) (14). To calculate the effect size 
(ES), the total sample size and the number of laboratory-
defined aspirin resistance patients were used. The I
2
 test was 
used to evaluate heterogeneity between studies, which was 
classified as low, moderate and high (25%, 50% and 75%, 
respectively) (15). To assess, the role of variables such as 
sample size, or geographic area of studies was conducted. To 
ensure the stability of the results and to investigate the 
impact of each study on the final outcome, a sensitivity 
analysis was performed. To examine the effect of gender in 
laboratory-defined aspirin resistance, odds ratio (OR) was 
calculated. Also, studies were ranked based on the year of 
publication and cumulative meta-analysis was conducted to 
examine the trend of changes over time. Visual inspection of 
the funnel plot and Egger’s regression test were used to 
evaluate the publication bias (16). Figures with p<0.05 were 
considered statistically significant. All statistical analyses 
were conducted with the commercial software 




After the initial search of the databases, out of a list of 
2079 items, 65 studies were included and analyzed based on 
the above-mentioned inclusion/exclusion criteria (figure 1) 
(17-81). The overall number of CVD patients was 10,729. 
Appendix 1 shows the characteristics of the studies retained 
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Appandix 1: The characteristics of the studies 
Author Year Country Sample size Male Female ER LL UL QOS 
Aksu 2014 Turkey 203 128 75 0.300 0.241 0.367 10 
Akturk 2014 Turkey 134 126 19 0.164 0.111 0.237 8 
Abid 2012 Tunisie 79 38 35 0.241 0.159 0.347 10 
Abaci 2005 Turkey 184 96 88 0.152 0.107 0.212 10 
Aksu 2009 Turkey 220 161 59 0.382 0.320 0.448 10 
arslan 2015 Turkey 50 34 16 0.320 0.206 0.460 8 
Aydinalp 2008 Turkey 338 168 170 0.240 0.197 0.288 8 
Bach 2009 Germany 42 30 12 0.143 0.066 0.283 10 
Blann 2012 UK 169 138 31 0.290 0.227 0.363 10 
Çagirci 2009 Turkey 32 23 9 0.339 0.232 0.464 9 
Cagirci 2010 Turkey 44 34 10 0.477 0.336 0.623 8 
Acikel 2009 Turkey 97 65 32 0.299 0.216 0.397 8 
Cao 2016 China 1130 872 258 0.503 0.474 0.532 10 
Cao 2012 China 304 NA NA 0.204 0.162 0.253 9 
Catakoglu 2009 Turkey 100 77 23 0.140 0.085 0.223 8 
Cetin 2014 Turkey 70 28 42 0.371 0.267 0.490 8 
Chadha 2016 Indian 126 100 26 0.357 0.278 0.444 8 
Chakroun 2007 Tunisia 191 172 19 0.157 0.112 0.216 8 
Chen 2007 China 468 323 145 0.274 0.235 0.316 9 
Chen 2005 China 117 88 29 0.188 0.127 0.269 10 
Chen 2004 China 151 114 37 0.192 0.137 0.263 9 
Cheng 2007 China 54 34 20 0.296 0.190 0.430 9 
Christiaens 2002 France 50 44 6 0.200 0.111 0.333 8 
Christiaens 2008 France 97 76 21 0.299 0.216 0.397 10 
Chu 2010 New Zealand 314 162 152 0.477 0.336 0.623 10 
Crowe 2005 Ireland 31 25 6 0.419 0.261 0.596 10 
Cuisset 2009 France 136 102 34 0.014 0.091 0.209 10 
Doly 2016 France 64 44 20 0.141 0.75 0.249 10 
Dorsch 2007 North Carolina 94 28 66 0.298 0.214 0.398 10 
Durmaz 2008 Ankara 69 54 15 0.261 o.o71 0.377 7 
Floyd 2014 UK 93 32 61 0.183 0.117 0.275 10 
Foussas 2009 Greece 469 344 125 0.258 0.220 0.300 10 
Glauser 2009 USA 200 101 99 0.065 0.038 0.109 9 
Golanski 2004 Poland. 24 24 0 0.167 0.064 0.369 8 
Grove 2010 Denmark 64 49 15 0.125 0.064 0.231 9 
Hiyasat 2012 Germany. 100 NA NA 0.750 0.656 0.825 10 
Hobikoglu 2005 Turkey 204 148 56 0.338 0.277 0.406 10 
Hobikoglu 2005 Turkey 100 72 28 0.270 0.192 0.365 10 
Ibrahim 2013 Malaysia 74 63 11 0.162 0.094 0.264 10 
Kim 2011 Korea 220 162 58 o.109 0.050 0.222 10 
Kim 2010 Korea 55 NA NA 0.177 0.132 0.233 10 
Kranzoeer 2006 Germany 55 NA NA 0.455 0.329 0.586 8 
Liu 2013 China 246 167 79 0.248 0.198 0.306 8 
Lopez-Farre 2006 Spain 38 15 4 0.500 0.346 0.654 8 
Lordkipanidze 2007 Canada 201 155 46 0.597 0.528 0.663 10 
Macchi 2002 France 72 55 17 0.292 0.199 0.406 10 
Manica 2012 USA 108 58 50 0.065 0.031 0.130 7 
Marcucci 2006 Italy 147 116 31 0.299 0.231 0.378 10 
Mirkhel 2006 USA 123 64 64 0.081 0.044 0.145 7 
Narvaez 2007 Spain 268 185 83 0.164 0.124 0.213 10 
Ozben 2010 Turkey 200 111 89 0.210 0.159 0.272 10 
Pamukcu 2006 Turkey 234 182 52 0.190 0.126 0.277 8 
Pamukcu 2007 Turkey 505 382 123 0.234 0.199 0.273 9 
Poston 2005 American 225 127 98 0.298 0.242 0.361 10 
Salama 2012 Egypt 50 40 10 0.220 0.126 0.355 9 
Schwartz 2008 USA 184 115 69 0.038 0.018 0.078 10 
Serdar 2013 Turkey 100 65 35 0.220 0.149 0.312 8 
Stejskal 2006 Czech 103 66 37 0.447 0.354 0.543 10 
Stolarek 2015 Poland 194 150 44 0.062 0.035 0.106 10 
Tantry 2005 USA 223 131 92 0.090 0.059 0.135 10 
Vivas 2011 USA 141 123 18 0.504 0.422 0.585 7 
Wang 2011 UK 111 80 31 0.297 o.220 0.389 10 
Ziaee 2004 IRAN 170 91 79 0.753 0.683 0.812 9 
Angiolillo 2006 Italy 105 82 23 0.444 0.363 0.529 9 
Pamukcu 2007 Turkey 234 182 52 0.222 0.174 0.280 9 
E R =Event rate             L L=Lower limit         U L=Upper limit             Q O S=Quality of score 
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Pooled prevalence of aspirin resistance in patients with 
cardiovascular disease: The overall prevalence of aspirin 
resistance in CVD patients was 24.7% ([95%CI 21.4-28.4], 
I
2











































Figure 2: Pooled aspirin resistance prevalence rate in cardiovascular patients with its 95% confidence interval based on the 
Dersimonian-Laird random-effect model of the included studies in the present systematic review and meta-analysis 
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper Relative Relative 
rate limit limit Z-Value p-Value weight weight
Christiaens,2002 0.200 0.111 0.333 -3.921 0.000 1.39
Macchi,2002 0.292 0.199 0.406 -3.422 0.001 1.53
Chen,2004 0.192 0.137 0.263 -6.954 0.000 1.59
Chen,2005 0.188 0.127 0.269 -6.183 0.000 1.55
Crowe,2005 0.419 0.261 0.596 -0.894 0.371 1.38
Golanski,2005 0.167 0.064 0.369 -2.938 0.003 1.10
Hobikoglu,2005 0.338 0.277 0.406 -4.535 0.000 1.65
Hobikoglu, 2005 0.270 0.192 0.365 -4.416 0.000 1.57
Tantry,2005 0.090 0.059 0.135 -9.888 0.000 1.56
Abaci,2006 0.152 0.107 0.212 -8.369 0.000 1.59
Angiolillo,2006 0.444 0.363 0.529 -1.288 0.198 1.63
Kranzhofer,2006 0.455 0.329 0.586 -0.673 0.501 1.51
Marcucci,2006 0.299 0.231 0.378 -4.723 0.000 1.62
Mirkhel,2006 0.081 0.044 0.145 -7.350 0.000 1.43
Pamukcu,2006 0.190 0.126 0.277 -5.822 0.000 1.54
Poston,2006 0.298 0.242 0.361 -5.885 0.000 1.65
Stejskal,2006 0.447 0.354 0.543 -1.082 0.279 1.60
Pamukcu, 2007 0.222 0.174 0.280 -7.967 0.000 1.64
Chakroun,2007 0.157 0.112 0.216 -8.449 0.000 1.60
Chen,2007 0.274 0.235 0.316 -9.421 0.000 1.68
Cheng,2007 0.296 0.190 0.430 -2.902 0.004 1.47
Dorsch,2007 0.298 0.214 0.398 -3.802 0.000 1.57
Lopez-Farre,2007 0.500 0.346 0.654 0.000 1.000 1.44
Lordkipanidze,2007 0.597 0.528 0.663 2.733 0.006 1.65
Narvaez,2007 0.164 0.124 0.213 -9.869 0.000 1.63
Pamukcu,2007 0.234 0.199 0.273 -11.295 0.000 1.68
Christiaens,2008 0.299 0.216 0.397 -3.843 0.000 1.57
Durmaz,2008 0.261 0.171 0.377 -3.799 0.000 1.51
Schwartz,2008 0.038 0.018 0.078 -8.382 0.000 1.35
Acikel,2009 0.299 0.216 0.397 -3.843 0.000 1.57
Aksu,2009 0.382 0.320 0.448 -3.472 0.001 1.66
Bach,2009 0.143 0.066 0.283 -4.063 0.000 1.26
Cagirci,2009 0.339 0.232 0.464 -2.493 0.013 1.51
Catakoglu,2009 0.140 0.085 0.223 -6.299 0.000 1.49
Cuisset,2009 0.140 0.091 0.209 -7.349 0.000 1.54
Foussas,2009 0.258 0.220 0.300 -10.010 0.000 1.68
Aydinalp,2010 0.240 0.197 0.288 -9.061 0.000 1.67
Cagirci,2010 0.477 0.336 0.623 -0.301 0.763 1.47
Chu,2010 0.096 0.068 0.133 -11.709 0.000 1.61
Glauser,2010 0.065 0.038 0.109 -9.295 0.000 1.49
Grove,2010 0.125 0.064 0.231 -5.148 0.000 1.36
Kim,2010 0.177 0.132 0.233 -8.695 0.000 1.62
Ozben,2010 0.210 0.159 0.272 -7.632 0.000 1.63
Kim,2011 0.109 0.050 0.222 -4.855 0.000 1.27
Vivas,2011 0.504 0.422 0.585 0.084 0.933 1.63
Ziaee,2011 0.753 0.683 0.812 6.267 0.000 1.62
Abid,2012 0.241 0.159 0.347 -4.368 0.000 1.52
Blann,2012 0.290 0.227 0.363 -5.283 0.000 1.63
Cao,2012 0.204 0.162 0.253 -9.567 0.000 1.65
Salama,2012 0.220 0.126 0.355 -3.707 0.000 1.41
Wang,2012 0.297 0.220 0.389 -4.142 0.000 1.59
Ibrahim,2013 0.162 0.094 0.264 -5.207 0.000 1.45
Liu,2013 0.248 0.198 0.306 -7.515 0.000 1.65
Manica,2013 0.065 0.031 0.130 -6.829 0.000 1.34
Serdar,2013 0.220 0.149 0.312 -5.243 0.000 1.55
Aksu,2014 0.300 0.241 0.367 -5.519 0.000 1.64
Akturk,2014 0.164 0.111 0.237 -6.979 0.000 1.56
Cetin,2014 0.371 0.267 0.490 -2.127 0.033 1.54
Floyd,2014 0.183 0.117 0.275 -5.582 0.000 1.51
Hiyasat,2014 0.750 0.656 0.825 4.757 0.000 1.56
Arslan,2015 0.320 0.206 0.460 -2.486 0.013 1.47
Stolarek,2015 0.062 0.035 0.106 -9.123 0.000 1.47
Cao,2016 0.503 0.474 0.532 0.178 0.858 1.70
Chadha,2016 0.357 0.278 0.444 -3.161 0.002 1.61
Doly,2016 0.141 0.075 0.249 -5.034 0.000 1.38
0.247 0.214 0.284 -11.577 0.000
-2.00 -1.00 0.00 1.00 2.00
Favours A Favours B
Meta Analysis
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Results of subgroup analysis: Based on sample size, 
geographic regions, year of study publication, quality of 
studies and gender of participants, the results of the different 
subgroup-analyses are shown in table 1. 
Prevalence of aspirin resistance and sample size: Based 
on the sample size, the prevalence of aspirin resistance 
reported in 39 studies with up to 150 participants was 26.4% 
[95%CI 22.2-31], compared to 22.5% [95%CI 21.6-28.6], 
reported by 26 studies with more than 150 participants. This 
difference was not statistically significant (p=0.47). 
Prevalence of aspirin resistance and geographical 
background: According to the geographic region, the 
prevalence in Asia was reported by 11 studies and was 
27.3% [95%CI 22.4-29.4%], while the rate in Europe was 
available in 41 studies (25.7%, [95%CI 22.4-29.4%]). In 
Africa, a prevalence of 19.5% [95%CI 16.2-25.5] was found, 
whereas in America was of 19.1% [95%CI 10.2-32.2]. The 
difference in prevalence rate broken down to geographic 
background was statistically significant (p<0.0001). 
Prevalence of aspirin resistance and year of publication: 
Between 2000 and 2006, 17 studies reported a prevalence 
rate of 25% [95%CI 19.7-31.2], whereas between 2007 and 
2012, the prevalence was 24.5% [95%CI 20.2-29.2] 
according to 34 studies. Finally, in the years 2013-2017, the 
prevalence was 24.8% [95%CI 16.9-34.9]. From a statistical 
standpoint, the prevalence rate of aspirin resistance among 
CVD patients was not significant on the basis of the years of 
study (p=0.63). 
Prevalence of aspirin resistance and quality of studies: 
Based on the checklist used to evaluate the quality of the 
studies, 5 studies with a score of 4 to 7 reported a prevalence 
of 42.9% [95%CI 28.9-59.1], whereas in 60 studies with a 
score of 8 to 10, the prevalence was 23.5% [95%CI 17.5-
26.7], although this difference was not statistically 
significant (p=0.15). 
Prevalence of aspirin resistance and gender: In 39 studies, 
data were suitable for calculating the prevalence of 
laboratory-defined aspirin resistance stratified according to 
gender. More in details, the prevalence in men was 23.5% 
[95%CI 19.5-28.0] and in women 26.9% [95%CI 22.4-31.9]. 
This difference was statistically significant (p<0.0001). An 
OR of 1.16 [95%CI 0.87-1.54] was computed (figure 3). 
This finding showed that women are at increased risk of 
laboratory-defined aspirin resistance compared to men. 
Results of cumulative meta-analysis for the prevalence of 
in patients with cardiovascular disease: The studies were 
ranked according to the year of publication and cumulative 
meta-analysis was performed. The results did not change 
before and after this analysis, and the prevalence was 24.7% 
[95%CI 21.4-28.4]. Appendix 2 shows cumulative meta-
analysis based on the year of publication. Studies were also 
ranked by sample size. The results did not change before and 
after the cumulative meta-analysis and the prevalence was 
stable. Appendix 3 shows cumulative meta-analysis based on 
the year of publication. 
Results of sensitivity analysis for the prevalence of 
aspirin resistance in patients with cardiovascular disease: 
Sensitivity analysis was carried out to ensure the stability of 
the results of the studies. The prevalence of aspirin resistance 
before and after the sensitivity analysis did not change with 
the exclusion of each study (Appendix 4). 
Publication bias: The Egger’s regression test results are 
presented in Appendix 5. Observation of the asymmetry of 
the funnel plot indicated that there was an evidence of 















Appendix 5: The Funnel plot of the studies included in 
the present systematic review and meta-analysis 
 
Discussion 
The aim of this study was to determine the prevalence 
rate of laboratory defined aspirin resistance in CVD patients 
worldwide. The concept laboratory defined aspirin 
resistance has been argued since 1980s, but discussions in 
late literature have centralized on evidence why aspirin 
resistance is probably a mistake (82, 83). To the best of our 
knowledge, systematic search of the literature, meta-analysis 
and extensive statistical analyses (sub-group analysis, 
sensitivity analysis, cumulative meta-analysis) were the 























Funnel Plot of Standard Error by Logit event rate
 
Caspian J Intern Med 2020; 11(2):124-134 
130                                                                               Ebrahimi P, et al. 
major strengths of this study. The findings showed that the 
prevalence of laboratory-defined aspirin resistance in CVD 
patients was 24.7%, with a higher rate among women. This 
study, pooling together different investigations reporting 
conflicting results, has enabled to overcome their statistical 
limitations and shortcomings. Some studies have, indeed, 
found that women have more or equal responsiveness rate to 
aspirin than men, being successful in controlling the COX-1 
pathway, whilst other studies have shown no difference 
between female and male (7). According to other scholars, 
women would have a worse prognosis than men, whereas 
other studies reported that the biochemical mechanism of 
laboratory-defined aspirin resistance is unknown, even 
though female sex hormones may play an important role (84, 
85). We computed an OR of 1.16 [95%CI 0.87-1.54], 
showing that women are at increased risk of laboratory-
defined aspirin resistance compared to men. 
Another important finding of the study is that, the 
prevalence rate is different in different regions of the world, 
putatively because of differences in the biological and 
genetic make-up of individuals. A higher prevalence was 
found in Asia, while the lowest rate was computed for 
studies carried out in America. 
These findings pave the way for a personalized treatment, 
in that individual factors seem to affect the response to 
aspirin. Clinically speaking, there are some conditions 
known for predisposing patients to higher rate of aspirin 
resistance. For instance, several studies have shown that 
patients undergoing coronary artery bypass grafting 
(CABG), which results in endothelial tissue damage to the 
saphenous vein graft, or coronary interventions, are more 
likely to become resistant to aspirin, with high thrombin 
level and platelet activation (10, 86). This suggests that, after 
CABG surgery or other interventions, patients should be 
closely monitored and should receive plavix, alternatively, 
anti-thrombotic drugs. Usually, aspirin resistance after a 
CABG surgery persists for a short term period (22, 87). This 
temporal laboratory-defined aspirin resistance was in a 
population of patients who had withstand coronary bypass. 
Although no adaptation with treatment is a momentous cause 
of laboratory aspirin resistance, patient dependency 
treatment was determined in few studies (88-90). Cotter et 
al, have indicated no adaptation to treatment is a significant 
moderator of negligible consequence. It is substantial to 
appraise whether patients take their medicines in clinical 
conditions or in studies that measure the effect of 
prescription drugs (89, 90). According to research, another 
strategy to control laboratory defined aspirin resistance is the 
administration of vitamin D (91). Furthermore, patients not 
practicing enough physical activity and/or with increased 
blood glucose should require higher aspirin doses (92, 93). 
However, despite its strengths, the present systematic 
review and meta-analysis suffers from some limitations, that 
hinder generalization of the present findings and call up for 
caution in interpreting results. The major drawback is given 
by the heterogeneity between studies and the evidence of 
publication bias. Another limitation is given by the 
methodological and quality differences among the studies. 
As such, further larger high-qualities studies in the field are 
warranted. Moreover, available study data did not allow to 
investigate the impact of possible risk factors associated with 
the prevalence of laboratory-defined aspirin resistance. 
The findings of the present systematic review and meta-
analysis showed that the prevalence of laboratory defined 
aspirin resistance in CVD patients was 24.7%. Doctors and 
healthcare providers should pay special attention to this, 
since lack of awareness could cause problems and increase 
mortality in these patients, if not properly treated with higher 
aspirin doses. It is suggested that one way to overcome the 
problem of laboratory defined aspirin resistance perhaps is to 
give the patient more medicine. However, this cannot be the 
result of the study, and more specific studies are required, in 
the way that the method of platelet related assay, the length 
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